Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) in a research report issued on Monday. The firm set a "hold" rating on the biopharmaceutical company's stock.

A number of other brokerages also recently issued reports on VNDA. HC Wainwright initiated coverage on Vanda Pharmaceuticals in a report on Thursday, October 31st. They set a "buy" rating and a $18.00 price target on the stock. Cantor Fitzgerald boosted their price target on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an "overweight" rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Stock Down 0.8 %

NASDAQ:VNDA traded down $0.04 during trading hours on Monday, hitting $5.05. 483,877 shares of the company's stock traded hands, compared to its average volume of 1,276,989. The firm has a market cap of $294.46 million, a P/E ratio of -18.29 and a beta of 0.77. Vanda Pharmaceuticals has a 52 week low of $3.46 and a 52 week high of $6.75. The business's fifty day simple moving average is $4.80 and its two-hundred day simple moving average is $5.26.

Insiders Place Their Bets

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the company's stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the transaction, the director now owns 44,857 shares in the company, valued at approximately $231,910.69. This represents a 10.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 8.90% of the company's stock.

Institutional Trading of Vanda Pharmaceuticals

A number of hedge funds have recently made changes to their positions in VNDA. Meeder Asset Management Inc. bought a new position in shares of Vanda Pharmaceuticals during the 2nd quarter valued at $39,000. ORG Wealth Partners LLC bought a new position in shares of Vanda Pharmaceuticals during the 3rd quarter valued at $40,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 4,374 shares during the period. SG Americas Securities LLC bought a new position in shares of Vanda Pharmaceuticals during the 2nd quarter valued at $61,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Vanda Pharmaceuticals by 18.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 2,425 shares during the period. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.